Colon Cancer

9 protocols meet the specified criteria

OCR12704

NSABP Patient Registry and Biospecimen Profiling Repository (MPR-1)

OCR13631

Molecular Analysis for Therapy Choice (MATCH)

OCR15732

Phase II Trial of the PARP1 Inhibitor, Niraparib, in BAP1 and other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)

OCR15832

A Phase II Study of the Dual Immune Checkpoint Blockade with Durvalumab (MEDI4736) plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy

OCR16937

A Phase 1 Study of NLG802 for Adult Patients with Recurrent Advanced Solid Tumors

OCR17028

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

OCR17279

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

OCR17458

Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

OCR18120

A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated